多形性胶质母细胞瘤 (GBM) 是最常见的中枢神经系统癌症，尽管有多种有效的介质，但其生存率却很低：强化细胞毒治疗、嵌合抗原受体 (CAR)-T 细胞治疗、病毒治疗、过继细胞治疗、免疫检查点阻断治疗、放射治疗疗法和疫苗疗法。本综述探讨了免疫靶向的基本概念，并研究了检查点阻断药物、CAR-T 细胞、溶瘤病毒、组合多模式免疫疗法和癌症疫苗等产品。根据最近对这些策略的研究、正在进行的临床试验的结果以及之前的试验结果，讨论了克服 GBM 治疗中当前限制和挑战的新方法。版权所有 © 2024 Elsevier Ltd. 保留所有权利。

Glioblastoma multiforme (GBM) is the most common CNS cancer, it has dismal survival rates despite several effective mediators: intensified cytotoxic therapy, chimeric antigen receptor (CAR)-T cell therapy, viral therapy, adoptive cell therapy, immune checkpoint blockade therapy, radiation therapy and vaccine therapy. This review examines the basic concepts underlying immune targeting and examines products such as checkpoint blockade drugs, CAR-T cells, oncolytic viruses, combinatory multimodal immunotherapy and cancer vaccines. New approaches to overcoming current constraints and challenges in GBM therapy are discussed, based on recent studies into these tactics, findings from ongoing clinical trials, as well as previous trial results.Copyright © 2024 Elsevier Ltd. All rights reserved.